Altus has initiated patient dosing in phase-II trial for ALTU-238 in growth hormone deficiency pediatric subjects. ALTU-238 is a long-acting, extended release formulation of recombinant human growth hormone.
The phase-II ALTU-238 pediatric trial is being conducted in approximately 18 clinical sites in the US, and targets enrolling 36 growth hormone deficient pediatric patients.
Georges Gemayel, President and CEO of Altus, said: “Moving this pediatric trial forward is an important step in re-establishing the value of the ALTU-238 program and Altus.”
“This phase 2 pediatric trial is the fifth clinical study to evaluate ALTU-238. Previous ALTU-238 studies have demonstrated pharmacokinetic and pharmacodynamic (PK/PD) profiles that are supportive of and consistent with a once-per-week dosing regimen,” he added.